PURPOSE: To prospectively evaluate the capability of dynamic perfusion MRI for assessment of disease severity and progression to pulmonary arterial hypertension (PAH) in connective tissue disease (CTD) patients. MATERIALS AND METHODS: In all, 18 gender- and age-matched CTD patients without and with PAH and nine healthy volunteers underwent dynamic perfusion MRI, Doppler echocardiography, and pulmonary function test. Disease severity of CTD was assessed in terms of diffusing capacity for carbon monoxide (%DL(CO)) and estimated systolic pulmonary arterial pressure (sPAP), and progression of PAH in terms of pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR). From calculated pulmonary perfusion parameter maps, means of pulmonary blood flow (mPBF), pulmonary blood volume (mPBV), and mean transit time (mMTT) were determined as averages of all region of interest (ROI) measurements. To determine disease severity in CTD, all parameters were statistically correlated with sPAP and %DL(CO). To determine progression to PAH, all parameters were statistically correlated with mPAP and PVR. RESULTS: All pulmonary perfusion parameters correlated significantly with sPAP and % DL(CO) (P < 0.05). mPBF and mPBV correlated significantly with mPAP and moderately with PVR (P < 0.05). CONCLUSION: Dynamic perfusion MRI can be used for assessment of disease severity and progression of PAH in CTD patients. (c) 2008 Wiley-Liss, Inc.
PURPOSE: To prospectively evaluate the capability of dynamic perfusion MRI for assessment of disease severity and progression to pulmonary arterial hypertension (PAH) in connective tissue disease (CTD) patients. MATERIALS AND METHODS: In all, 18 gender- and age-matched CTDpatients without and with PAH and nine healthy volunteers underwent dynamic perfusion MRI, Doppler echocardiography, and pulmonary function test. Disease severity of CTD was assessed in terms of diffusing capacity for carbon monoxide (%DL(CO)) and estimated systolic pulmonary arterial pressure (sPAP), and progression of PAH in terms of pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR). From calculated pulmonary perfusion parameter maps, means of pulmonary blood flow (mPBF), pulmonary blood volume (mPBV), and mean transit time (mMTT) were determined as averages of all region of interest (ROI) measurements. To determine disease severity in CTD, all parameters were statistically correlated with sPAP and %DL(CO). To determine progression to PAH, all parameters were statistically correlated with mPAP and PVR. RESULTS: All pulmonary perfusion parameters correlated significantly with sPAP and % DL(CO) (P < 0.05). mPBF and mPBV correlated significantly with mPAP and moderately with PVR (P < 0.05). CONCLUSION: Dynamic perfusion MRI can be used for assessment of disease severity and progression of PAH in CTDpatients. (c) 2008 Wiley-Liss, Inc.
Authors: Andrew J Swift; Smitha Rajaram; Helen Marshall; Robin Condliffe; Dave Capener; Catherine Hill; Christine Davies; Judith Hurdman; Charlie A Elliot; Jim M Wild; David G Kiely Journal: Eur Radiol Date: 2011-10-13 Impact factor: 5.315
Authors: Yoshiharu Ohno; Joon Beom Seo; Grace Parraga; Kyung Soo Lee; Warren B Gefter; Sean B Fain; Mark L Schiebler; Hiroto Hatabu Journal: Radiology Date: 2021-04-06 Impact factor: 29.146
Authors: Andrew J Swift; Jim M Wild; Scott K Nagle; Alejandro Roldán-Alzate; Christopher J François; Sean Fain; Kevin Johnson; Dave Capener; Edwin J R van Beek; David G Kiely; Kang Wang; Mark L Schiebler Journal: J Thorac Imaging Date: 2014-03 Impact factor: 3.000
Authors: Andrew J Swift; Adam Telfer; Smitha Rajaram; Robin Condliffe; Helen Marshall; Dave Capener; Judith Hurdman; Charlie Elliot; David G Kiely; Jim M Wild Journal: Pulm Circ Date: 2014-03 Impact factor: 3.017